Beyond Quitting: Uncovering Gaps in Reporting Dual Use in Trials of E-Cigarettes for Smoking Cessation
Clicks: 1
ID: 325598
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #63 of 121 articles by views in nicotine & tobacco research : official journal of the society for research on nicotine and tobacco
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 121 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
INTRODUCTION: Nicotine e-cigarettes (ECs) have been evaluated as aids for combustible cigarette (CC) cessation and in a recent evidence synthesis, were determined to improve quit rates versus nicotine replacement therapy (NRT). Dual EC/CC use is a common real-world tobacco use pattern with distinct dependence and harm exposure implications but is rarely treated as a trial outcome. METHODS: We reviewed peer-reviewed trials included in a recent Cochrane review and meta-analysis of EC for smoking cessation to determine whether dual EC/CC use prevalence at trial endpoints (1) was directly reported (or derivable from reported outcomes) and (2) the specificity with which dual use was defined. Further, we calculated the prevalence of dual use at the most commonly reported post-intervention timepoint (i.e., 4 weeks). RESULTS: Of 71 eligible peer-reviewed trials, 57 (80.3%) did not report dual use prevalence; 1 (1.4%) allowed derivation; and 12 (16.9%) reported dual use as an outcome. Only one of those twelve that reported dual use specified both the frequency and duration of use of each product in their definition of dual use. Across reported timepoints, dual use prevalence in EC arms ranged from 6.6% to 89.5%; the mean prevalence at 4 weeks was 42.6%. CONCLUSIONS: Dual use is infrequently and inconsistently reported in EC smoking cessation trials, limiting interpretation of both clinical efficacy and public health impact. We provide recommendations for defining dual use as a trial outcome and for standardizing reporting.
| Reference Key |
openalex_W7203769302
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Makayla S Stewart, Abigail E Hoyt, Sara Fernandez, Maggie M. Sweitzer, Lauren R. Pacek, F. Joseph McClernon |
| Journal | nicotine & tobacco research : official journal of the society for research on nicotine and tobacco |
| Year | 2026 |
| DOI |
10.1093/ntr/ntag180
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.